Trajectory of bodyweight and skeletal muscle mass in patients treated with nintedanib for idiopathic pulmonary fibrosis
Summary: Background and Aims: Nintedanib is currently a therapeutic option for idiopathic pulmonary fibrosis (IPF). Weight loss is a common complication of IPF and a side effect of nintedanib, inducing loss of skeletal muscle mass and musculoskeletal dysfunction. Thus far, few clinical studies have...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Jezik: | English |
| Izdano: |
Elsevier
2024-12-01
|
| Serija: | Clinical Nutrition Open Science |
| Teme: | |
| Online dostop: | http://www.sciencedirect.com/science/article/pii/S2667268524000834 |